COILED THERAPEUTICS PLC (COIL) — Introduction to the Company

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the Rockford Therapeutics PLC Introductory Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and can be submitted at any time by the Q and A tab situated on the right hand corner of your screen. Just simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company will review all questions submitted today and publish responses where it is appropriate to do so. Before we begin, I'd I'd like to submit the following poll. I'd now like to hand you over to doctor Greta Robertson, chief scientific officer and Stephen West, executive chairman. Good morning to you. Good morning, everyone. My name is Steve West. I am the cofounder and chairman of Rockford Therapeutics. I'm a chartered accountant with over twenty six years of experience working with companies, predominantly with growth companies, and know the public market sphere very well. And I'll just pass you over quickly to Graham just to give you a bit of background on himself before we dive into the presentation. Hi. Yeah. I'm doctor Graham Robertson. I'm the chief scientific officer of Luramid that was recently acquired by Rockford. I've been connected with the MidKind program to develop drugs targeting Midkind since 2015 and oversaw the transition from an original Sydney based company into the Rockford London based entity. So back to you, Steve. Thanks, Graham. So diving straight in, disclaimer, we'll skip over that. I can read that at your leisure. But as an introduction to the company, so we are a UK biotech company. We're listed on the on the London main market, and the ticket code is ROQ. We're actually listed ...